MMWR Morb Mortal Wkly Rep. 2023 Apr 14;72(15):398-403. doi: 10.15585/mmwr.mm7215a4.
As of December 31, 2022, a total of 29,939 monkeypox (mpox) cases* had been reported in the United States, 93.3% of which occurred in adult males. During May 10-December 31, 2022, 723,112 persons in the United States received the first dose in a 2-dose mpox (JYNNEOS) vaccination series; 89.7% of these doses were administered to males (1). The current mpox outbreak has disproportionately affected gay, bisexual, and other men who have sex with men (MSM) and racial and ethnic minority groups (1,2). To examine racial and ethnic disparities in mpox incidence and vaccination rates, rate ratios (RRs) for incidence and vaccination rates and vaccination-to-case ratios were calculated, and trends in these measures were assessed among males aged ≥18 years (males) (3). Incidence in males in all racial and ethnic minority groups except non-Hispanic Asian (Asian) males was higher than that among non-Hispanic White (White) males. At the peak of the outbreak in August 2022, incidences among non-Hispanic Black or African American (Black) and Hispanic or Latino (Hispanic) males were higher than incidence among White males (RR = 6.9 and 4.1, respectively). Overall, vaccination rates were higher among males in racial and ethnic minority groups than among White males. However, the vaccination-to-case ratio was lower among Black (8.8) and Hispanic (16.2) males than among White males (42.5) during the full analytic period, indicating that vaccination rates among Black and Hispanic males were not proportionate to the elevated incidence rates (i.e., these groups had a higher unmet vaccination need). Efforts to increase vaccination among Black and Hispanic males might have resulted in the observed relative increased rates of vaccination; however, these increases were only partially successful in reducing overall incidence disparities. Continued implementation of equity-based vaccination strategies is needed to further increase vaccination rates and reduce the incidence of mpox among all racial and ethnic groups. Recent modeling data (4) showing that, based on current vaccination coverage levels, many U.S. jurisdictions are vulnerable to resurgent mpox outbreaks, underscore the need for continued vaccination efforts, particularly among racial and ethnic minority groups.
截至 2022 年 12 月 31 日,美国共报告了 29939 例猴痘(mpox)病例*,其中 93.3%发生在成年男性中。在 2022 年 5 月 10 日至 12 月 31 日期间,美国有 723112 人接种了两剂 mpox(JYNNEOS)疫苗系列中的第一剂;这些剂量中有 89.7%是给男性接种的(1)。当前的猴痘疫情 disproportionately 影响了同性恋、双性恋和其他与男性发生性关系的男性(MSM)以及种族和少数民族群体(1,2)。为了检查发病率和疫苗接种率方面的种族和族裔差异,计算了发病率和疫苗接种率的比率比(RR)和疫苗接种与病例比,并评估了 18 岁及以上男性(男性)(3)中这些措施的趋势。除了非西班牙裔亚裔(亚裔)男性外,所有种族和族裔少数群体的男性发病率均高于非西班牙裔白人(白人)男性。在 2022 年 8 月疫情高峰时,非西班牙裔黑人和非洲裔(黑人)和西班牙裔或拉丁裔(西班牙裔)男性的发病率高于白人男性(RR 分别为 6.9 和 4.1)。总体而言,少数族裔群体中男性的疫苗接种率高于白人男性。然而,在整个分析期间,黑人(8.8)和西班牙裔(16.2)男性的疫苗接种与病例比均低于白人男性(42.5),这表明黑人男性和西班牙裔男性的疫苗接种率与发病率不成比例(即这些群体的未满足的疫苗接种需求更高)。增加黑人男性和西班牙裔男性的疫苗接种率可能导致了观察到的相对较高的疫苗接种率;然而,这些增加在一定程度上成功地减少了整体发病率差异。需要继续实施基于公平的疫苗接种策略,以进一步提高疫苗接种率,并减少所有种族和族裔群体的猴痘发病率。最近的建模数据(4)显示,根据目前的疫苗接种覆盖率水平,美国许多司法管辖区容易出现反弹的猴痘疫情,这突显出需要继续开展疫苗接种工作,特别是在种族和族裔少数群体中。
MMWR Morb Mortal Wkly Rep. 2023-4-14
MMWR Morb Mortal Wkly Rep. 2023-6-9
J Public Health Manag Pract.
MMWR Morb Mortal Wkly Rep. 2022-11-11
MMWR Morb Mortal Wkly Rep. 2022-8-12
MMWR Morb Mortal Wkly Rep. 2023-5-26
MMWR Morb Mortal Wkly Rep. 2022-10-28
Open Forum Infect Dis. 2025-8-14
Open Forum Infect Dis. 2025-7-16
BMC Public Health. 2024-9-10
AJPM Focus. 2024-2-8
Med Clin North Am. 2024-3
MMWR Morb Mortal Wkly Rep. 2022-11-11
MMWR Morb Mortal Wkly Rep. 2022-10-28
MMWR Morb Mortal Wkly Rep. 2022-10-28
MMWR Morb Mortal Wkly Rep. 2022-10-28
JMIR Public Health Surveill. 2016-4-21